Detalhe da pesquisa
1.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
N Engl J Med
; 389(22): 2039-2051, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870976
2.
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Gynecol Oncol
; 156(3): 535-544, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31924332
3.
Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
Cancer
; 125(24): 4435-4441, 2019 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31503332
4.
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Cancer
; 125(15): 2610-2620, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31173362
5.
Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.
Invest New Drugs
; 36(3): 476-486, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29177975
6.
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
Gynecol Oncol
; 146(3): 531-537, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28651804
7.
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.
Clin Pharmacol Ther
; 115(3): 468-477, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776107
8.
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Lung Cancer
; 178: 166-171, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868177
9.
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36948506
10.
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
Nat Med
; 29(10): 2577-2585, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37710001
11.
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
; 25(2): 219-228, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34257408
12.
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).
JTO Clin Res Rep
; 2(2): 100104, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34589982
13.
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Cancer Med
; 10(11): 3565-3574, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33960681
14.
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies.
JTO Clin Res Rep
; 2(2): 100103, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34589981
15.
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
J Clin Oncol
; 39(30): 3391-3402, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34339292
16.
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer.
Data Brief
; 30: 105465, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32346557
17.
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.
Cancer Discov
; 10(8): 1194-1209, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414908
18.
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
J Clin Oncol
; 34(8): 786-93, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26371143
19.
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
Cancer Chemother Pharmacol
; 75(5): 1047-55, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25791363
20.
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Cancer Chemother Pharmacol
; 74(4): 729-37, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25100135